Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase I/II study of maternal mitochondria-enriched autologous CD34+ cells in children with Pearson syndrome
MOH_2018-12-09_004790Phase 2Active, not recruiting
- Sponsor
- Minovia Therapeutics
- Start
- Aug 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MNV-101 in Pearson syndrome, sponsored by Minovia Therapeutics. Started Aug 2018; status: active, not recruiting.
02
Drugs
MNV-101
03
Conditions
Pearson syndrome
Beyond the preview
Go deeper on MOH_2018-12-09_004790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-09_004790.